Valuation: Quest PharmaTech Inc

Market Cap 42.28L 29.81L 26.15L 24.14L 22.31L 29Cr 43.13L 2.9Cr 1.13Cr 14Cr 1.12Cr 1.09Cr 48Cr P/E 2025
-3.29x
P/E 2026 1.18x
Enterprise Value 52.14L 36.76L 32.24L 29.77L 27.51L 35Cr 53.18L 3.58Cr 1.39Cr 17Cr 1.38Cr 1.35Cr 60Cr EV / Sales 2025
-
EV / Sales 2026 -
Free-Float
83.12%
Yield 2025 *
-
Yield 2026 -
Manager TitleAgeSince
Chief Executive Officer - 17/06/2004
Director of Finance/CFO - 01/01/2005
Director TitleAgeSince
Director/Board Member - 17/06/2004
Chairman - 05/07/2021
Director/Board Member - 05/07/2021
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-15.38% - - 29.8L
-0.24%+1.85%+3.13%+8.40% 4.97TCr
-0.39%+1.16%+420.53%+597.10% 4.05TCr
-2.76%+3.71%+23.34%+56.62% 3.43TCr
-2.28%-0.15%+23.36%-7.54% 3.48TCr
-0.79%+2.02%+3.83%+36.42% 2.7TCr
+3.08%+2.43% - - 1.66TCr
-3.01%-2.57%+64.22%+119.04% 1.56TCr
-2.15%+6.87%+104.72%+102.56% 1.43TCr
-2.70%-2.04%+12.37%+17.77% 1.38TCr
Average -1.24%+3.99%+81.94%+116.30% 2.74TCr
Weighted average by Cap. -1.41%+4.37%+93.79%+134.05%

Financials

2025 2026
Net sales - -
Net income -18.01L -12.7L -11.14L -10.28L -10L -12Cr -18.37L -1.24Cr -48.03L -5.95Cr -47.69L -46.64L -21Cr 49.98L 35.24L 30.91L 28.54L 26.37L 34Cr 50.98L 3.43Cr 1.33Cr 17Cr 1.32Cr 1.29Cr 57Cr
Net Debt 8L 6L 5L 5L 4L 5.37Cr 8L 54.56L 21.2L 2.63Cr 21.05L 20.59L 9.12Cr 10L 7L 6L 6L 5L 6.65Cr 10.05L 67.65L 26.29L 3.26Cr 26.1L 25.53L 11Cr
Logo Quest PharmaTech Inc
Quest PharmaTech Inc. is a Canada-based biopharmaceutical company. The Company is developing products to improve the quality of life. The Company is also developing a proprietary MAb AR 9.6 targeting truncated MUC16 as theranostic agents for cancer. The Company has a 42.5% ownership interest in OncoQuest Inc. (OncoQuest), a Canadian biotechnology company developing combinatorial immunotherapy products for the treatment of cancer. OncoQuest’s technology platform included a panel of tumor antigen-specific monoclonal antibodies of the immunoglobulin G (IgG) and E (IgE) class targeting CA125, MUC1, PSA, Her2/neu, CA 19.9 and TAG72; and the application of combinatorial immunotherapy to enhance tumor specific immunity and clinical outcome. The Company also has a 23% ownership interest in OncoVent Co., Ltd. (OncoVent), which is developing antibody-based immunotherapeutic products for cancer for the Greater China territory.
Employees
-